8-K: BioMarin Reports Strong Q1 2024 Results, Driven by VOXZOGO Growth and Strategic R&D Prioritization

BioMarin announced record financial results for the first quarter of 2024, highlighted by a 9% year-over-year revenue increase and a 70% jump in GAAP diluted earnings per share, driven by strong VOXZOGO sales and strategic R&D focus.

Summary

• BioMarin reported total revenues of $649 million for the first quarter of 2024, a 9% increase compared to the same period in 2023, or 13% at constant currency.
• GAAP diluted earnings per share (EPS) reached $0.46, a 70% increase year-over-year, while non-GAAP diluted EPS was $0.71, an 18% increase.
• VOXZOGO net product revenues were $153 million, a 74% increase year-over-year, with the number of children treated increasing by over 100% year-over-year.
• The company reaffirmed its full-year 2024 total revenue guidance and raised its non-GAAP operating margin and non-GAAP EPS guidance.
• BioMarin accelerated three high-value R&D programs and discontinued four others as part of a strategic portfolio assessment.
• Over 3,100 children were being treated with VOXZOGO across 43 active markets by the end of the quarter, an increase of over 500 from the previous quarter.
• The company expects enrollment to begin in the second half of 2024 for studies of VOXZOGO in idiopathic short stature and multiple genetic short stature pathway conditions.
• The company expects the 52-week randomized, double-blind, placebo-controlled phase of the hypochondroplasia clinical trial to start mid-year and complete enrollment in the first half of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, particularly the growth in VOXZOGO sales and earnings per share. The strategic R&D prioritization and raised guidance further contribute to the positive outlook. However, challenges with ROCTAVIAN uptake and some product revenue declines temper the sentiment slightly.

Positives

• The company experienced strong revenue growth, driven by increased VOXZOGO sales.
• There was a significant increase in the number of children being treated with VOXZOGO.
• BioMarin achieved substantial growth in both GAAP and non-GAAP earnings per share.
• The company is actively prioritizing its R&D pipeline to focus on the most promising programs.
• Full-year 2024 guidance for non-GAAP operating margin and non-GAAP diluted EPS has been raised.
• The company has made progress in expanding the use of VOXZOGO into new indications.
• The first patient in Italy was treated with ROCTAVIAN following price approval.

Negatives

• Reimbursement and market access challenges continue to impact the uptake of ROCTAVIAN.
• NAGLAZYME product revenues decreased due to the timing of orders in certain countries.
• KUVAN product revenues declined due to generic competition.
• There was an increase in R&D and SG&A expenses due to the support of global VOXZOGO market expansion and clinical activities.

Risks

• The company faces challenges in securing reimbursement and market access for ROCTAVIAN.
• Generic competition continues to impact KUVAN product revenues.
• The company's financial performance is subject to fluctuations in foreign currency exchange rates.
• The success of the company's R&D programs is subject to clinical trial outcomes and regulatory approvals.
• The company's future performance is subject to macroeconomic and other external factors.

Future Outlook

BioMarin reaffirmed its full-year 2024 total revenue guidance and raised its non-GAAP operating margin and non-GAAP diluted EPS guidance. The company expects continued growth in VOXZOGO sales and is focused on advancing its strategic priorities, including expanding the use of VOXZOGO into new indications and accelerating key R&D programs.

Management Comments

• Alexander Hardy, President and Chief Executive Officer of BioMarin, stated that the company's execution led to double-digit revenue growth and an 18% increase in non-GAAP diluted earnings per share.
• Mr. Hardy also noted that the company made rapid progress on advancing its strategic priorities, including accelerating and maximizing the VOXZOGO opportunity, focusing R&D on the most productive assets, and increasing profitability.
• Mr. Hardy mentioned that the company was pleased with the outcome of its strategic R&D asset review, resulting in the acceleration and prioritization of the most potentially impactful medicines for patients.

Industry Context

This announcement reflects a trend in the biotechnology industry towards focusing on high-value assets and maximizing the potential of approved therapies. BioMarin's strategic R&D prioritization and focus on VOXZOGO align with this trend, as companies seek to optimize their pipelines and drive profitability. The company's focus on rare genetic disorders also positions it in a niche market with high unmet medical needs.

Comparison to Industry Standards

• BioMarin's 9% year-over-year revenue growth is solid compared to other mid-cap biotech companies, but the 13% growth at constant currency is more impressive, indicating strong underlying demand.
• The 70% increase in GAAP diluted EPS is significantly higher than many of its peers, suggesting strong operational efficiency and cost management.
• The 74% year-over-year growth in VOXZOGO revenue is exceptional, demonstrating the strong market demand for this therapy and the company's ability to execute its commercial strategy.
• Companies like Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN) also focus on specialty markets and have seen strong growth, but BioMarin's focus on rare genetic disorders provides a unique market position.
• The strategic R&D prioritization is similar to moves by other biotech companies like Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT), which are also focusing on high-potential programs and discontinuing less promising ones.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and strategic focus.
• Patients will benefit from the continued development and commercialization of innovative therapies.
• Employees may experience changes due to the R&D prioritization and organizational adjustments.
• Customers will benefit from the increased availability of VOXZOGO and other therapies.
• Suppliers may see changes in demand based on the company's strategic priorities.

Next Steps

• BioMarin will continue to focus on maximizing the VOXZOGO opportunity.
• The company will advance its three prioritized R&D programs.
• BioMarin will continue to focus on key elements critical to supporting ROCTAVIAN uptake in the U.S., Italy and Germany.
• The company will begin enrollment in studies for VOXZOGO in idiopathic short stature and multiple genetic short stature pathway conditions in the second half of 2024.
• The company will complete enrollment for the observational run-in study for hypochondroplasia by year-end.
• The company will start the 52-week randomized, double-blind, placebo-controlled phase of the hypochondroplasia clinical trial mid-year and complete enrollment in the first half of 2025.
• BioMarin will share more details at Investor Day on September 4th.

Key Dates

Keywords

BioMarin, VOXZOGO, ROCTAVIAN, Financial Results, Earnings, Revenue, R&D, Biotechnology, Rare Diseases, Achondroplasia, Hypochondroplasia, Growth Disorders, Gene Therapy